Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.48 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 9/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364483 | 1.00 | MEN1 (0.49) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL25029034 | 0.84 | DYRK1A (0.50) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL29361163 | 0.84 | DYRK1A (0.50) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL29364487 | 0.82 | GSK3B (0.48) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL25028649 | 0.82 | GSK3B (0.48) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL25029171 | 0.81 | DYRK1A (0.58) | GSK3BDYRK1ANFATC1CDK2ROCK2 | |
| SCHEMBL29364491 | 0.81 | DYRK1A (0.58) | GSK3BDYRK1ANFATC1CDK2ROCK2 | |
| SCHEMBL25028830 | 0.80 | DYRK1A (0.55) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL25029067 | 0.80 | GSK3B (0.46) | MEN1KMT2AATMGAAGSK3B | |
| SCHEMBL29364153 | 0.80 | GSK3B (0.46) | MEN1KMT2AATMGAAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-115996926-A | Indole compounds as androgen receptor modulators | 尼多生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MEN1 2818/4885KMT2A 1853/4885ATM 1579/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MEN1 2673/4885KMT2A 1683/4885ATM 1550/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | MEN1 2646/4885KMT2A 1758/4885ATM 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.